<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05115292</url>
  </required_header>
  <id_info>
    <org_study_id>BJ-005-01-001US</org_study_id>
    <nct_id>NCT05115292</nct_id>
  </id_info>
  <brief_title>A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma</brief_title>
  <official_title>A First-in-Human, Multicenter, Open-label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BJ Bioscience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BJ Bioscience, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a first-in-human, Phase 1 study to evaluate the safety, tolerability, and&#xD;
      pharmacokinetics of BJ-005 in patients with advanced solid tumor or lymphoma. BJ-005 is a&#xD;
      recombinant bifunctional molecule, composed of a humanized anti-PD-L1 IgG1 monoclonal&#xD;
      antibody (mAb) fused with a portion of the extracellular domain of human TGF-β receptor II&#xD;
      (TGF-βRII).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">October 20, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the incidence and frequency of adverse events following intravenous (IV) infusion of BJ-005 in patients with advanced solid tumor or lymphoma. The assessment will be conducted per CTCAE 5.0 throughout the conduct of the study.</measure>
    <time_frame>60 days after the last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of BJ-005 following IV infusion in patients with advanced solid tumor or lymphoma.</measure>
    <time_frame>60 days after the last dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Advanced Solid Tumor or Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BJ-005 dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BJ-005 cohort expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BJ-005</intervention_name>
    <description>dosed with intravenous infusion</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female ≥ 18 years.&#xD;
&#xD;
          2. Willing and able to provide signed and dated informed consent prior to any&#xD;
             study-related procedures and willing and able to comply with all study procedures.&#xD;
&#xD;
          3. Histologically or cytologically confirmed advanced solid tumors or lymphoma&#xD;
&#xD;
          4. Measurable or evaluable disease per RECIST v1.1&#xD;
&#xD;
          5. ECOG performance status 0 or 1&#xD;
&#xD;
          6. Life expectancy ≥3 months&#xD;
&#xD;
          7. Adequate hepatic function&#xD;
&#xD;
          8. Calculated creatinine clearance (CrCL) &gt; 50 mL/min (Cockroft-Gault Equation)&#xD;
&#xD;
          9. Adequate Hematological function&#xD;
&#xD;
         10. Prothrombin time, international normalized ratio or activated partial thromboplastin&#xD;
             time &lt; 1.5 × ULN&#xD;
&#xD;
         11. Recovery, to Grade 0-1, from adverse events related to prior anticancer therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior therapy with anti PD-L1/TGFβRⅡ targeting treatment.&#xD;
&#xD;
          2. Symptomatic primary central nervous system (CNS) tumor of CNS metastases.&#xD;
&#xD;
          3. Uncontrolled hypertension.&#xD;
&#xD;
          4. Significant thrombotic or hemorrhagic events.&#xD;
&#xD;
          5. Prior CAR-T therapy&#xD;
&#xD;
          6. Severe cardiovascular disease.&#xD;
&#xD;
          7. Active infection requiring therapy&#xD;
&#xD;
          8. Active HIV, hepatitis B or hepatitis C virus&#xD;
&#xD;
          9. Active tuberculosis&#xD;
&#xD;
         10. Anticancer therapy or radiation therapy within 5 half-lives or 4 weeks (whichever is&#xD;
             shorter) prior to study entry&#xD;
&#xD;
         11. Pregnant or breast-feeding females&#xD;
&#xD;
         12. Active or history of autoimmune disease or inflammatory disorders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vicky Gao, MD</last_name>
    <role>Study Director</role>
    <affiliation>BJ Bioscience, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joe Zhang, MD</last_name>
    <phone>203-437-6518</phone>
    <email>joe.zhang@bjbioscience.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Next Oncology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrae Vandross,, M.D.</last_name>
      <phone>210-580-9500</phone>
      <email>mailto:avandross@nextoncology.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

